Histone deacetylases (HDACs) are important regulators of gene expression and cell differentiation. The HDAC inhibitors have recently been considered as potential novel neuroprotective drugs for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). A major limitation, however, lies in the broad spectrum of action of currently available HDAC inhibitors that may cause a variety of toxic side effects. The mRNA expression levels of the HDAC isoforms HDACs 1 to 11 have previously been characterized in rat brain but have not been studied in human tissue. Using in situ hybridization histochemistry and immunohistochemistry we assessed the distribution and expression levels of HDACs 1 to 11 in postmortem ALS and control brain and spinal cord specimens (n = 6 cases each) to determine alterations in the mRNA expression pattern that could provide a basis for disease-specific therapies. We found a reduction of HDAC 11 mRNA and increased HDAC 2 levels in ALS brain and spinal cord compared with controls. A more precise knowledge of the disease-related expression pattern could lead to the development of more specific pharmacotherapeutic approaches.
INTRODUCTION
Acetylation and deacetylation of lysine residues of core histones and also other intracellular proteins play a major role in the regulation of gene expression (1, 2) . Acetylation of histones mainly enhances accessibility of transcription factors; therefore, it correlates with transcriptional activity and determines specific temporal and spatial gene expression patterns (3, 4) .
Hypoacetylation is mostly associated with transcriptional repression and gene silencing, but histone deacetylation can lead to activation of gene transcription (5, 6) . Acetylation or deacetylation of other proteins also apparently contributes to transcriptional activation or repression (6, 7) . Therefore, acetylation can be considered as a molecular Bon-off switch[ of genes (1) .
Histone deacetylases (HDACs) are grouped into 4 classes: Class I (HDACs 1Y3, 8) , Class II (HDACs 4Y7, 9, 10), Class III (also known as sirtuins, SIRT 1Y7), and Class IV (HDAC 11); each has distinct localizations, substrates, and physiological roles. In brief, Class I HDACs are localized in the nucleus and are mainly modulated by phosphorylation and subsequent association with multiunit protein complexes. Class II HDACs can shuttle between the nucleus and the cytoplasm and are thus regulated by subcellular compartmentalization depending on their phosphorylation status. They bind to 14-3-3-proteins that leads to expulsion from the nucleus, that is, inactivation of transcriptional repression (8) . A dependence of nucleocytoplasmic shuttling of HDACs 4 and 5 on calcium influx through N-methyl-d-aspartic acid receptors has been reported in neurons (9) . Both Classes I and II HDACs require zinc as a cofactor to unfold their catalytic activity (10) . In contrast to Classes I, II, and IV HDACs, Class III HDACs (sirtuins) are nicotinamide adenine dinucleotide dependent. The HDAC 11 is the only HDAC IV enzyme and can be distinguished by its distinct structural and functional properties. It can form complexes with HDAC 6 (11, 12) and is predominantly located in the nucleus. Overexpression of HDACs has been described in vitro in tumor cells but also after hypoxia, hypoglycemia, and serum deprivation (1) .
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by progressive loss of motor neurons in the primary motor cortex and the ventral horn of the spinal cord. The average survival is between 3 and 5 years, and therapeutic options are currently marginal. Transcriptional dysregulation occurs both in human sporadic ALS and in the G93A mouse model (13Y17). A direct relationship between neuronal apoptosis and modifications of histone acetylation and deacetylation has been shown in chronic neurodegeneration (18, 19) . Treatment of healthy cells with HDAC inhibitors induces apoptotic cell death, whereas in neurodegenerative diseases, the acetylation status of histones decreases; this is initially triggered by loss of the histone acetyl transferases cAMP response element-binding (CREB) binding protein and p300 and subsequent Boverweight[ of HDACs (19) . When the homeostatic balance between acetylation and deacetylation is lost, however, transcriptional alteration leads to decreased expression of survival-promoting molecules and increased transcription of proapoptotic genes (8) .
Specific roles for HDACs 4 and 6 have been described. Augmentation of HDAC 6 in vitro can induce autophagy and, therefore, could compensate for dysfunction of the ubiquitinproteasome system. This could counteract the accumulation of misfolded proteins, an important pathogenetic mechanism in neurodegenerative diseases such as Huntington disease and ALS (20, 21) . On the other hand, inhibition of HDAC 6 restored intracellular transport dysfunction in striatal cells transfected with mutant Huntingtin by increased tubulin acetylation (22) .
For HDAC 4, regular expression was shown to be in the cytoplasm of neurons, whereas excitotoxic stimuli led to increased intranuclear shuttling that was linked to apoptotic cell death (23) .
Because of the variety of effects that can be triggered by HDAC inhibition, HDAC enzymes have become potential therapeutic targets for several types of diseases, including neoplastic, cardiovascular, and neurodegenerative disorders. Depending on the genes involved, neuroprotective effects may arise from increased expression of antioxidant, antiinflammatory, or antiapoptotic genes induced by HDAC inhibition. In particular, inhibitors of Classes I and II HDACs have been studied with respect to their neuroprotective potential in animal models of neurodegenerative disorders (24Y26). For example, in the G93A transgenic ALS mouse model, the HDAC inhibitors phenylbutyrate and sodium phenylbutyrate showed neuroprotective and life spanYprolonging effects that correlated with increased gene expression of antiapoptotic and antioxidant factors such as Bcl-2 or magnesium superoxide dismutase (24, 27, 28) . The anticonvulsant drug valproic acid also possesses HDAC-inhibitory effects and has been shown to be neuroprotective in mouse models of ALS and spinal muscular atrophy (29Y32).
Here, we characterized HDAC mRNA and protein expression patterns in postmortem brain and spinal cord tissue of ALS patients to define disease-specific patterns that may provide a basis for the development of more specific and potentially less toxic HDAC inhibitors.
MATERIALS AND METHODS
Postmortem brain and spinal cord specimens from 6 sporadic ALS patients aged between 44 and 82 years with a definite diagnosis of ALS according to the El Escorial criteria (i.e. showing signs of upper and lower motor neuron affection in at least 3 body regions) (42) and brain specimens of 6 and spinal cord specimens of 5 age-matched control patients with no evidence of neurological or psychiatric disease were studied (Table) . All ALS cases were examined by a neuropathologist of the neuropathology department of Hannover Medical School after Nissl staining. The typical neuropathologic features of ALS, including rarefactions of motor neurons in the spinal cord and motor cortex, gliosis of the spinal cord, and pallor of the corticospinal tracts, were documented in all cases. In the ALS spinal cord sections, there were higher proportions of small motoneurons, but there was still considerable motoneuron preservation, consistent with shrinkage but not complete loss of motor neurons (33, 34) .
The integrity of the RNA up to 36 hours postmortem has previously been demonstrated (35, 36) . This was confirmed by running RNA aliquots extracted from motor cortex and spinal cord samples using TRIzol reagent (Invitrogen, Carlsbad, CA) and subsequent purification by the RNeasy Mini Kit (Qiagen, Hilden, Germany) on a 1% agarose gel in Tris/Borate/EDTA, Brain and lumbar spinal cord specimens were cut into coronal slices of 1-cm thickness and rapidly frozen on dry ice. Twelve-micrometer-thick sections of the precentral gyrus (Brodmann Area 4) and lumbar spinal cord (L2Y4) were cut Amyotrophic lateral sclerosis (ALS) Cases 1 to 3 and control Cases 1 to 3 were used for initial in situ hybridization (ISH) and immunohistochemistry experiments. Additional ISH experiments were performed in ALS Cases 4 to 6 (motor cortex and spinal cord) and control Cases 4 to 6 (motor cortex) and 4 to 5 (spinal cord) in experiments using the histone deacetylases (HDAC) 2, 5, and 11 oligonucleotides to confirm the differential expressions of HDAC 2 and 11.
ALS, amyotrophic lateral sclerosis; F, female; LMN, lower motor neuron; M, male; NA, not applicable.
on a cryostat, thaw-mounted onto poly-L-lysine-coated slides, fixed for 5 minutes in 4% phosphate-buffered paraformaldehyde, and stored in 96% ethanol at 4-C until use. In situ hybridization histochemistry was performed, as previously described (37) . For each oligonucleotide probe, tissue sections were processed in parallel to obtain x-ray and emulsion-dipped autoradiograms in adjacent slices. Slides were hybridized for 24 hours at 42-C with labeled probe diluted in hybridization buffer (50% formamide, 4Â saline sodium citrate, 5Â Denhardt solution, 10% dextran sulfate) to a final concentration of 0.07 pmol/mL. After washing in 1Â saline sodium citrate at 56-C for 30 minutes, neighboring sections were either exposed to Biomax x-ray film (Kodak, Stuttgart, Germany) for 3 weeks or dipped in NTB-2 nuclear track emulsion (Kodak). Dipped sections were counterstained with 0.05% thionin, dehydrated, and coverslipped. For a negative control, a 100-fold excess of nonlabeled oligonucleotides was added to the radioactive probe and applied to the adjacent section, leading to a complete suppression of the signal (not shown). Semiquantitative analysis of film autoradiograms was performed as previously described (37) . In brief, optical density readings were separately taken over Layers I to II, III to V (containing the motor neurons), and VI of the primary motor cortex and over the ventral and dorsal horns of the spinal cord sections by matching the autoradiogram readings to adjacent Nissl-stained sections. Absolute values of radioactivity were determined from 14 C plastic standards (Amersham, Freiburg, Germany) on the same sheet of film (ImageJ software, National Institutes of Health). Quantified hybridization signals for the patient and the control group were compared using Student t-test.
Cellular expression patterns of the mRNA transcripts were microscopically determined throughout the cortical layers by classifying the amount of silver grains over individual cells at the Nissl-counterstained sections as strong, moderate, or weak according to a visual analogue scale.
For immunohistochemistry, additional fresh-frozen sections were identically prepared, fixed in paraformaldehyde, and rinsed in Tris buffered saline buffer. For antigen retrieval of HDAC 11, sections were pretreated with 1% sodium dodecyl sulfate for 5 minutes. Further immunohistochemical staining was performed using the DAKO System (DAKO, Glostrup, Denmark). Endogenous peroxidase was blocked with peroxidase clock (DAKO-Peroxidase). After preincubation with antibody diluent (DAKO) for 1 hour at room temperature, sections were incubated with polyclonal rabbit antibodies directed against HDAC 2 (dilution 1:200; Santa Cruz Biotechnology, Santa Cruz, CA) and HDAC 11 (dilution 1:100; Abgent, San Diego, CA) overnight at 4-C, followed by an incubation with anti-rabbit labeled horseradish peroxidase polymer for 40 minutes and staining with 3-amino-9-ethylcarbazole (AEC+) chromogen (DAKO). The sections were counterstained with hematoxylin.
RESULTS
Tissues from 3 ALS and 3 control cases (primary motor cortex and lumbar spinal cord) were initially investigated. For HDAC 2 and HDAC 11, there were significant ALS-specific differences in mRNA expression levels. For HDAC 5, there was a trend toward a reduced expression in the ventral horn in the ALS specimens. Therefore, we performed additional in situ hybridization experiments using 3 additional ALS and control brains and 3 ALS and 2 control spinal cords for these 3 oligonucleotide probes (Fig. 1) .
At both the macroscopic and microscopic levels, the highest mRNA expression levels were observed for HDAC 2 in the motor cortex (most intense in Layers IIIYV), followed by HDACs 11 and 5. In the spinal cord, HDAC 2 also showed the highest expression levels, and moderate expression was seen for HDACs 5 and 11. Comparatively weak mRNA signals were observed for HDACs 1, 3, 4, 6, 7, 9, and 10 ( Fig. 1) .
HDAC 2 mRNA
In ALS samples, HDAC 2 expression was significantly higher than in the controls in the primary motor cortex (up to 3-fold) and in both the ventral and dorsal horns of the spinal cord samples (Fig. 1) . The controls showed similar HDAC 2 levels in the ventral and dorsal horns. Separate densitometric analysis of the ventral and dorsal horns in ALS samples, however, revealed lower HDAC 2 mRNA levels in the ventral horn than in the dorsal horn (Figs. 1, 2 ). At the light microscopic level, these differences could mainly be attributed to lower signal intensity in the large motor neurons in the ventral horn than in dorsal horn neurons and interneurons (Fig. 3) .
HDAC 11
In contrast to HDAC 2, the second highest mRNA expression level for HCAC 11 was seen in the control tissues, both in motor cortex and spinal cord. In the ALS specimens, HDAC 11 mRNA was significantly decreased in the motor cortex in Laminae III to VI and in both dorsal and ventral horns of the spinal cord. Expression levels were only slightly more elevated than those of HDAC 1. There were no differences between cortical layers or between ventral and dorsal horns (Fig. 1) . These results correlated with those of the emulsion-dipped slides in that there was a general decrease in grain density over neurons and non-neuronal cells in the ALS versus the control motoneurons (Figs. 3C, D) .
By immunohistochemistry, HDAC 2 was detected in the nuclei of motor neurons in both the patients and control groups, with increased signal intensity in ALS brain and spinal cord compared with controls (Figs. 4AYD) . For HDAC 11, immunohistochemistry revealed more diffuse staining pattern in both nucleus and cytoplasm and with lower intensity in the ALS sections (Figs. 4EYH) .
DISCUSSION

Differential HDAC Expression Patterns in Rodent and Human CNS
Broide et al (10) characterized HDACs 1 to 11 mRNA expressions in 50 regions of rat CNS using in situ hybridization. In the motor cortex, they found high levels of HDACs 3, 4, 5, and 11, similar to our results on HDACs 5 and 11 mRNA in brain and spinal cord (10) . In general, lower expression levels were seen in rat spinal cord than in motor cortex, with highest levels for HDACs 3, 5, and 11. By contrast, in human samples, we found higher HDAC 2 mRNA levels that were higher than those of HDAC 11. One could speculate from this observation that HDAC 2 plays a more important role in maintaining the acetylation-deacetylation equilibrium in human tissue than in rodents. Differences in expression levels between humans and rodents could be of importance in the context of preclinical drug trials in animal models.
HDAC Expression Patterns in ALS
We found lesser HDAC 11 mRNA expression in ALS motor cortex and spinal cord and increased expression of HDAC 2 mRNA in ALS motor cortex and spinal cord, with a regional difference between the ventral and dorsal horns. For HDAC 11, these differences were not specific for the region containing motor neurons (Layers IIIYV of the precentral gyrus or the ventral horn), suggesting that the change in expression is not motor neuron specific.
The finding of decreased HDAC 2 mRNA levels in the ventral horn compared with the dorsal horn in ALS patients cannot be attributed to motor neuron loss because decreased expression levels in the ventral horn were not a general finding in our study. The comparatively increased levels of HDAC 2 in the dorsal horn in the ALS samples could mean that this is a general feature of the disease not specific to motor neurons (i.e. consistent with other data showing that ALS primarily but not exclusively affects the motor system). Whether increased HDAC 2 expression in the ALS tissues is a reaction to cytotoxic stimuli (e.g. oxidative stress or excitotoxicity) or if increased HDAC 2 expression itself can trigger cell death cannot be determined by analysis of endstage postmortem specimens. Moreover, because the motor neurons are still detectable in end-stage tissue, they may be more resistant than those that had already undergone degeneration; one could speculate that the HDAC 2 upregulation may not represent a pathogenic but rather a protective feature.
The HDAC 2 is a Class I HDAC with localization in the nucleus. In a Drosophila model of ataxia telangiectasia, HDAC 2 was shown to interact functionally and physically with the neuroprotective gene ATM (ataxia telangiectasia mutated), which has a role in the control of cell cycle re-entry and the protection of postmitotic neurons. The ATM was directly deacetylated by HDAC 2 and therefore repressed in its transcription by HDAC 2 (38) . On the other hand, Huang et al (39) showed upregulation of HDAC 2 in colorectal cancer and cervical dysplasia and proved that siRNA-induced knockdown of HDAC 2 increased apoptotic cell death. A correlation between HDAC 2 activity and oxidative stress was observed in BEAS-2B cells, leading to increased production of inflammatory genes (40) . In a mouse model of muscular dystrophy, selectively elevated levels of HDAC 2 were detected in muscles, and downregulation of HDAC 2 led to improvement of functional and morphological parameters. Downregulation of HDAC 2 could be induced by NO donors that leads to S-nitrosylation. The authors concluded that selective blockade of HDAC 2 could be a therapeutic strategy in Duchenne muscular dystrophy (41Y43). Our finding of increased HDAC 2 gene expression in ALS postmortem tissue could point toward a similar aspect for motor neuron diseases and suggests further exploration of HDAC 2 inhibition in relevant disease models.
The HDAC 11, which was significantly decreased in both ALS motor cortex and spinal cord, is a Class IV HDAC.
Physiologically, HDAC 11 is involved in the downregulation of the interleukin 10 gene in antigen-presenting cells. Lack of HDAC 11 could, therefore, lead to the impairment of antigenspecific T-cell responses (44) . In a rat oligodendrocyte cell line, a role of HDAC 11 interacting with HDAC 3 in oligodendrocyte and neuronal development was shown (45, 46) . High levels of HDAC 11 were detected in cancer cell lines, which led to the speculation that increased HDAC 11 gene expression plays a role in tumor cell growth (12) . A specific role for HDAC 11 in neurons has not yet been defined so far.
In summary, HDAC inhibitors have emerged as promising drug candidates for the treatment of a variety of neurodegenerative diseases. The mode of action of the currently available HDAC inhibitors, however, is still very nonspecific and often associated with considerable toxicity. Moreover, the mechanisms of action of individual HDAC enzymes and the deleterious or beneficial effects of changes in HDAC expression levels need to be further elucidated both in vitro and in vivo. The precise characterization of ALS-related alterations in HDAC expression levels and in particular the upregulation of HDAC 2 in ALS motor neurons could allow for further disease-specific development of novel pharmacotherapeutic approaches.
